Profilo
Isaac Devash worked as Director at Scinai Immunotherapeutics Ltd. from 2017 to 2021.
Education includes an MBA from Harvard University and an undergraduate degree from The Wharton School of the University of Pennsylvania.
Posizioni attive di Isaac Devash
| Società | Posizione | Inizio |
|---|---|---|
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures invests in companies located in Israel. The firm focuses on life-sciences, biopharma, digital health and medical technology companies. It provides financing for early and late stage capital requirements with an investment size of USD 10 - 30 million. The firm makes follow-on investments and also acts as lead investor. | Investitore di Private Equity | - |
Precedenti posizioni note di Isaac Devash
| Società | Posizione | Fine |
|---|---|---|
| BIONDVAX PHARMACEUTICALS LTD | Direttore/Membro del Consiglio | 27/12/2021 |
Formazione di Isaac Devash
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. Pharmaceuticals: OtherHealth Technology Operates as a biopharmaceutical company that develops, manufactures and commercializes immunomodulation therapies for infectious diseases | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures invests in companies located in Israel. The firm focuses on life-sciences, biopharma, digital health and medical technology companies. It provides financing for early and late stage capital requirements with an investment size of USD 10 - 30 million. The firm makes follow-on investments and also acts as lead investor. | Finance |
















